SOURCE-LINKED STUDY SUMMARY
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Abstract summarizedQuality not appraised
- What was studied
- The trial compared several weekly retatrutide regimens with placebo and dulaglutide for glucose control and body weight over 24 to 36 weeks.
- Who / model studied
- Participants were adults aged 18-75 years with type 2 diabetes, HbA1c of 7·0-10·5%, and BMI of 25-50 kg/m².
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- At 36 weeks, body weight fell dose-dependently, reaching 16·94% in the retatrutide 12 mg group versus 3·00% with placebo and 2·02% with dulaglutide.
- Limitations & context
- Only 79% of participants completed study treatment. Methodological quality was not formally appraised here.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(23)01053-x